GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Price-to-Operating-Cash-Flow

BioXcel Therapeutics (BioXcel Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 01, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-05-01), BioXcel Therapeutics's share price is $2.54. BioXcel Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.34. Hence, BioXcel Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for BioXcel Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

BTAI's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

BioXcel Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.91. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.34.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -20.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -40.70% per year.

During the past 8 years, BioXcel Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -20.30% per year. The lowest was -176.30% per year. And the median was -49.80% per year.


BioXcel Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for BioXcel Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Price-to-Operating-Cash-Flow Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

BioXcel Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioXcel Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, BioXcel Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Price-to-Operating-Cash-Flow falls into.



BioXcel Therapeutics Price-to-Operating-Cash-Flow Calculation

BioXcel Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=2.54/-5.336
=

BioXcel Therapeutics's Share Price of today is $2.54.
BioXcel Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.34.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

BioXcel Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics (BioXcel Therapeutics) Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Executives
Vimal Mehta director, officer: CEO, President, Secretary 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Richard I Steinhart officer: Chief Financial Officer 125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez officer: SEE REMARKS C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Krishnan Nandabalan director, 10 percent owner 228 VILLAGE POND ROAD, GUILFORD CT 06437
Akrati Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello 10 percent owner 10 TEMPLETON ROAD, WALLINGFORD CT 06492
Krunal Dilip Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Alka Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Pardeep Kumar Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Anita Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437

BioXcel Therapeutics (BioXcel Therapeutics) Headlines

From GuruFocus